...A. Proposal 5 would eliminate the requirement that 80% of the outstanding shares approve certain corporate actions. B. We grew our top line, advanced our pipeline, expanded manufacturing capacity to meet increasing demand, and delivered innovative new medicines to more than 58 million people around the world. C. We delivered strong results in 2024 propelled by the performance of Mounjaro and Zepbound as well as Verzenio. D. We started eight new Phase 3 programs and disclosed Phase 3 data from 21 trials, which included 17 major publications in top tier medical journals. E. Notable among these were positive data readouts for tirzepatide, imlunestrant, and insulin efsitora alfa; and the initiation of Phase 3 programs for lepodisiran, remternetug, and olomorasib. F. We also added 14 new programs to the early-phase pipeline. G. We received U.S. regulatory approval for two new medicines in 2024, Kisunla for Alzheimer's disease and Ebglyss for moderate to severe atopic dermatitis, as well as many...
